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Background: -Conotoxins possess interesting blocking effects on voltage-gated sodium channels (Navs).
Results: Based on two known -conotoxins, we designed miniaturized peptides that potently and selectively block Navs,
although they do not contain an -helix.
Conclusion: Peptidomimetics constitute a valuable tool to develop novel, synthetic Nav blockers.
Significance:Our compounds prove to be an ideal starting platform in the search for therapeutics to treat Nav-related diseases.
To date, cone snail toxins (“conotoxins”) are of great interest
in the pursuit of novel subtype-selective modulators of voltage-
gated sodium channels (Navs). Navs participate in a wide range
of electrophysiological processes. Consequently, their malfunc-
tioning has been associated with numerous diseases. The devel-
opment of subtype-selective modulators of Navs remains highly
important in the treatment of such disorders. In current
research, a series of novel, synthetic, and bioactive compounds
were designed based on two naturally occurring -conotoxins
that target Navs. The initial designed peptide contains solely 13
amino acids and was therefore named “Mini peptide.” It was
derived from the-conotoxins KIIIA and BuIIIC. Based on this
Mini peptide, 10 analogues were subsequently developed, com-
prising 12–16 amino acids with two disulfide bridges. Following
appropriate folding and mass verification, blocking effects on
Navs were investigated. The most promising compound estab-
lished an IC50 of 34.1 0.01 nM (R2-Midi on Nav1.2). An NMR
structure of one of our most promising compounds was deter-
mined. Surprisingly, this structure does not reveal an -helix.
We prove that it is possible to design small peptides based on
known pharmacophores of -conotoxins without losing their
potency and selectivity. These data can provide crucial material
for further development of conotoxin-based therapeutics.
Voltage-gated sodium channels (Navs)3 are important trans-
membrane proteins with respect to generating as well as prop-
agating action potentials in excitable cells (e.g. neuronal cells
and muscular cells). Defective Navs cause several diseases or
channelopathies like epileptic disorders (1), neuromuscular
diseases (2), and cardiomyopathies (3). Blocking the aberrant
Na current can be effective in treating these disorders. In the
past, nonspecific Nav blockers like antiepileptic drugs, anticon-
vulsants, or antiarrhythmics have been widely utilized as ther-
apeutics (4). However, their use remains limited due to
unwanted side effects.More selectiveNavs blockers are needed.
One group of peptides recently acquiring interest in this
respect is conotoxins. Conotoxins are biologically active com-
pounds isolated from the venom of cone snails (genus Conus).
Four families of conotoxins target Navs. These are categorized
according to either their functional agonistic or antagonistic
effects. -Conotoxins (5) and -conotoxins (6) produce agonis-
tic effects, whereas O-conotoxins (7) and -conotoxins (8)
bring about antagonistic effects. Several excellent reviews exist
on their discovery, description, and therapeutic potential
(9–11). The group of toxins that is of importance in the current
study is the -conotoxin family.
-Conotoxins display a typical folding pattern called frame-
work III. In this conformation, three conserved disulfide
bridges are formed between Cys1-Cys4, Cys2-Cys5, and Cys3-
Cys6 (Cys residues are numbered according to their order in the
total sequence) (9). They affect Navs by plugging into the pore
analogously to the guanidinium toxins tetrodotoxin and saxi-
toxin. However, they do not target precisely the same binding
area (12). Other contact points on the outer channel vestibule
are possibly also essential with respect to their binding (12–17).
It is their high potency as well as small size (16–26 AAs) and
selectivity that renders -conotoxins very interesting (18). The
latter characteristic in particular is a valuable quality for the
development of potential therapeutics. In our experiments, we
attempted to benefit from this feature.Our strategywas tomin-
iaturize-conotoxins as much as possible as well as to improve
their potency and selectivity. In addition, the peptides needed
to be druggable compounds, e.g. compounds that could be syn-
thesized economically. Removal of one disulfide bridge for
instance offers a large economic advantage. Moreover, it can
provide extra stability because reactive thiol groups of disulfide
bridges can catalyze degradation processes (19).
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Our starting point was a small and stable peptide of 13 AAs
derived from two naturally occurring -conotoxins, KIIIA
from Conus kinoshitai (20), and BuIIIC from Conus bullatus
(21). A series of 10 analogues were subsequently designed.
Although they only comprise 13–16 amino acids, all peptides
retained their blocking properties. Our most promising com-
pound exhibits an IC50 value of 34.1 nM on Nav1.2. In addition
to being a very potent blocker, it displays an interesting selec-
tivity for Nav1.2 over Nav1.4 and Nav1.6. An NMR structure of
one of ourmost promising compounds, namedMidi, was deter-
mined. Surprisingly, this structure does not reveal an -helix.
This unique feature has never been seen in any of the known
-conotoxins.
EXPERIMENTAL PROCEDURES
Chemical Synthesis of Synthetic Peptides and Analysis—The
following peptides were synthesized by Peptide 2.0 (Chantilly,
VA): Mini, Mini-R5A,Mini-R5E, Midi, Extra-Mini, EAD-Midi,
EAK-Midi, AA-Midi, and a Midi peptide with the following
requirements: a first disulfide bridge between Cys1-Cys13 and a
second bridge between Cys3-Cys14. The R-analogues of the
Midi peptide (R1-Midi, R2-Midi, and R3-Midi) were synthe-
sized by ShanghaiMocell Biotech (Shanghai, China). Puritywas
confirmed to be95% by reversed-phase HPLC on an analyti-
cal Vydac C18 column (218MS54, 4.6 250mm, 5-mparticle
size; Grace, Deerfield, IL) with a flow rate of 1 mlmin1. UV
absorbancewasmonitored at 214 and 280 nmwith a dual wave-
length absorbance detector. A linear gradient of 0–40% aceto-
nitrile in 40 min was used at a flow rate of 1 mlmin1. The
gradient was set by means of a mixture of solvent A (0.085%
(v/v) trifluoroacetic acid (TFA) in acetonitrile) and solvent B
(0.1% TFA (v/v) in water) with an initial concentration of 0%
solvent A. Molecular masses were validated on an LCQ Deca
XP electrospray ionization-quadrupole ion trap-mass spec-
trometer (Thermo Finnigan) in a positive ionization mode.
Folding of the Peptides—The Mini peptide was folded using
two strategies. The first strategy was executed in accordance
with previous strategies established by our laboratory (22) and
other groups (e.g. Ref. 23). A glutathione folding mixture was
prepared that contained 1 mM reduced glutathione, 1 mM oxi-
dized glutathione, 1 mM EDTA, and 100mMTris-HCl (pH 7.5).
The reduced Mini peptide was dissolved in 0.01% (v/v) TFA
before being added to the folding mixture with a final peptide
concentration of 112 M. At different time points (e.g. 30 s, 30
min, 24 h, and 1 week) subsequent to initiation of the folding
reaction, aliquots were withdrawn and quenched by acidifica-
tion with 8% formic acid. In the second folding strategy, pep-
tides were dissolved in the physiological buffer solution ND-96
(see “Heterologous Expression”). Folding mixtures were
retained at room temperature for at least 2–3 days. At different
time points following dissolution, aliquots were withdrawn.
Aliquots were analyzed with reversed-phaseHPLC bymeans of
an analytical Vydac C18 column as described in the previous
section. Masses of the folded peptides were validated by elec-
trospray ionization MS.
Heterologous Expression—Complementary DNA encoding
the Nav channels was subcloned into the corresponding vector:
rNav1.2/pLCT1 (NotI), rNav1.3/pNa3T (NotI), rNav1.4/pUI-2
(NotI), hNav1.5/pcDNA3.1 (XbaI), mNav1.6/pLCT1 (NotI),
rNav1.7/pBSTA.rPN1 (SacII), rNav1.8/pSP64T (XbaI), h1/
pGEM-HE (NheI), or r1/pSP64T (EcoRI). Following linear-
ization with the respective restriction enzymes (indicated in
parentheses), capped cRNAwas generated by in vitro transcrip-
tion using the T7 (for rNav1.2, rNav1.3, rNav1.4, mNav1.6,
rNav1.7, and h1) or the SP6 (for hNav1.5, rNav1.8, and r1)
mMESSAGE mMACHINE transcription kit (Ambion, Austin,
TX).
Stage V-VI oocytes were harvested by partial ovariectomy
from anesthetized Xenopus laevis frogs as described previously
(22).Oocyteswere incubated inND-96 solution (96mMNaCl, 2
mM KCl, 1.8 mM CaCl2, 2 mM MgCl2, and 5 mM HEPES (pH
7.4)) supplemented with 50 mg/liter gentamicin sulfate and 0.5
mM theophylline. Selected oocytes were injected with cRNA at
1–3 ng/nl. Injection was conducted utilizing a microinjector
(Drummond Scientific, Broomall, PA). Oocytes were stored for
1–5 days at 16 °C until sufficient expression of Navs was
achieved.
Electrophysiology—Whole-cell currents from oocytes were
recorded at room temperature (18–22 °C) by the two-electrode
voltage clamp technique using a GeneClamp 500 amplifier
(Molecular Devices, Sunnyvale, CA) controlled by a pClamp
data acquisition system (Molecular Devices). Oocytes were
placed in a bath containing ND-96 solution. Voltage and cur-
rent electrodes were filled with 3 M KCl, and the resistances of
both electrodes were maintained as low as possible (between
0.5 and 1.5 megaohms). The elicited currents were sampled at
20 kHz and filtered at 2 kHz using a four-pole, low pass Bessel
filter. To eliminate the effect of the voltage drop across the bath
grounding electrode, the bath potential was actively controlled
by a two-electrode bath clamp. Leak subtractionwas performed
using aP/4 protocol.
Whole-cell current traces were evoked every 5 s by a 100-ms
depolarization to the voltage corresponding to the maximal
activation of the Nav subtype in control conditions, starting
from a holding potential of 90 mV. Concentration-response
curves were constructed by adding different toxin concentra-
tions directly to the bath solution. The percentage ofNav block-
ade was plotted against the logarithm of the applied concentra-
tions and fitted with the Hill equation, y  100(1  (IC50/
[toxin]h)1 where y is the percentage of block, IC50 is the toxin
concentration at half-maximal efficacy, [toxin] is the toxin con-
centration, and h is the Hill coefficient.
To investigate the effects on the voltage dependence of acti-
vation, current traces were induced by 100-ms depolarizations
from a holding potential of 90 to 65 mV with 5-mV incre-
ments. The Na conductance was calculated from the currents
using Ohm’s law, gNa  INa/(V  Vrev) where INa is the Na
current peak amplitude at a given test potentialV andVrev is the
reversal potential. The values of gNa were normalized and plot-
ted as a function of voltage and fitted using the Boltzmann
equation, gNa/gmax  (1  exp(Vg  V)/k)1 where gmax is the
maximal gNa, Vg is the voltage corresponding to half-maximal
conductance, and k is the slope factor.
To investigate the effects on the steady-state inactivation
process, oocytes were depolarized using a standard two-step
protocol. From a holding potential of 90 mV, 100-ms pre-
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pulses were generated, ranging from90 to 65 mV with 5-mV
increments, immediately followed by a 100-ms test pulse to
10mV. The current amplitudes from the test pulse were nor-
malized to the maximal Na current amplitude Imax and plot-
ted as a function of the applied prepulse potential using the
Boltzmann equation, INa/Imax (1 exp(V Vh)/k)1 where
Imax is the maximal INa,Vh is the voltage corresponding to half-
maximal inactivation, V is the test voltage, and k is the slope.
Statistical analysis of the experiments was performed using a
one-way analysis of variance Bonferroni test (p 0.05). All data
are presented as means S.E. in general of at least three inde-
pendent experiments (n 3).
NMR Spectroscopy—NMR spectra were recorded with a 2
mM solution of folded Midi (200 l) in 100% D2O and in 80%
H2O and 20% D2O mixtures at 5 °C at 600 MHz on a Bruker
Avance II 600 spectrometer equippedwith a 5-mmTCIHCNZ
gradient cryoprobe. Spectra were processed using Topspin
(version 2.1; Bruker Biospin) and analyzed using CARA (ver-
sion 1.8.4) (24, 25).
In the one-dimensional and two-dimensional spectra in 80%
H2O, thewater signalwas suppressed using excitation sculpting
with gradients (26). The two-dimensional NOESY in H2O
(mixing times, 150 and 300 ms) was recorded with a sweep
width of 7210 Hz in both dimensions, 128 scans, 4096 data
points in t2, and 512 free induction decays in t1. A two-dimen-
sional total correlation spectroscopy spectrum in 80% H2O
with DIPSI2 sequence for mixing was recorded with a sweep
width of 7210Hz in both dimensions, 80 scans, 4096 data points
in t2, and 512 free induction decays in t1 (26, 27) A double
quantum-filtered correlation (COSY) spectrum in H2O was
acquired using a 3-9-19 pulse sequencewith gradients for water
suppression allowing for presaturation during relaxation delay
in cases of radiation damping (28–30).
Natural abundance 1H,13C heteronuclear single quantum
correlation in D2O was recorded with sensitivity enhancement
and gradient coherence selection optimized for selection of CH
groups (JCH  145 Hz) using 64 scans and 256/1024 complex
data points and 30,200/6010 Hz spectral widths in t1 and t2,
respectively. The two-dimensional heteronuclear single quan-
tum correlation-total correlation spectroscopy spectrum con-
sisted of a heteronuclear single quantum correlation building
block followed by a clean MLEV-17 total correlation spectros-
copy transfer step of 60-ms mixing time just prior to the refo-
cusing gradient with exactly the same spectral widths and num-
ber of points as heteronuclear single quantum correlation. The
data were apodized with a shifted sine-bell square function in
both dimensions of two-dimensional spectra.
Structural Constraints—Distance restraints were derived
fromNOESY spectra recorded with 150-msmixing times. Esti-
mated interproton distances were derived using the isolated
spin pair approximation, rij  rref (aref/aij)1⁄6 where rij is the
estimated interproton distance, rref is the fixed internal refer-
ence distance, and aref and aij are the NOE cross-peak intensi-
ties of the reference and estimated cross-peaks, respectively.
NOE interaction within geminal methylene pairs was used to
determine fixed internal reference distances of 1.8 Å. An exper-
imental error (20%) was used on the calculated interproton
distances. 3JHNH coupling constantsweremeasured fromdou-
ble quantum-filtered COSY spectra inH2O and then converted
to dihedral restraints as follows: 3JHNH  8 Hz,   120 
30°; 3JHNH 6 Hz, 60 30°.
Structure Calculations—All structure calculations were per-
formed by means of X-PLOR-NIH V3.851 (31). A set of 100
structures was generated by torsion angle molecular dynamics,
starting from an extended strand and using NMR-derived
restraints. After the torsion angle molecular dynamics round
(32), the majority of structures had converged to very similar
structures with similar total energies and no violations of the
NOE and dihedral restraints. Twenty lowest energy structures
were used for further refinement during the “gentle molecular
dynamics” round in explicit water (33). A box of water was
constructed andoptimized around selected structures obtained
from torsion angle dynamics. The final refinement commenced
with a 20-ps constant temperature molecular dynamics simu-
lation at 300 K (20,000 steps of 0.001 ps) and was followed by a
200-step conjugate gradient energy minimization of the aver-
age structure of the last 10 ps of the 20-ps simulation. Visual
representations of the molecule were obtained with PyMOL
Molecular Graphics System (version 1.3; Schro¨dinger, LLC).
RESULTS
Design Strategy
Mini Peptide—We attempted to design a chimeric, as much
as possible minimized peptide benefiting from the particular
characteristics of two -conotoxins, BuIIIC and KIIIA.
BuIIIC has recently been discovered in the venom of C. bul-
latus alongside BuIIIA and BuIIIB (21). Strikingly, they differ
greatly from previously isolated -conotoxins because they
only contain three residues in the second intercysteine loop as
opposed to four (Table 1A). BuIIICdemonstrates a strong block
on Nav1.4 (96% at 1 M) (21). We retained the structural char-
acteristics as well as its potent block.
An additional -conotoxin gaining our interest was KIIIA
because it is the smallest -conotoxin identified thus far, con-
taining 16 AAs (20). Its short first intercysteine loop contains
but one Asn residue, whereas other -conotoxins possess at
least three or even eight residues in this loop (Table 1A).
For construction of the chimeric Mini peptide, residues of
the three intercysteine loops were taken into consideration as
“building blocks.” The first loop is based on KIIIA and contains
an Asn residue. For the second loop, we considered the
sequences of BuIIIA, BuIIIB, and BuIIIC. BuIIIA and BuIIIB
incorporate Gly-Arg-Trp, whereas BuIIIC encompasses the
sequence Ser-Arg-Trp. A considerably larger number of
-conotoxins bear at least one Ser residue in the second loop
(Table 1A, 12 of 18). This proves to be a more favorable residue
from an evolutionary viewpoint rather than Gly (Table 1A, six
of 18). Hence the sequence of BuIIIC was selected to construct
the second loop. Concerning the third loop, BuIIIC and KIIIA
contain identical residues. In addition, comparable sequences
are found in other -conotoxins (e.g. SIIIA, SmIIIA, and CIIIA;
Table 1A). Therefore, these BuIIIC/KIIIA residues were incor-
porated in the chimeric peptide.
We integrated recent results by Han et al. (34) into our design
strategy. They illustrated that the first disulfide bridge between
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Cys1 and Cys9 in KIIIA is removable, almost without affecting the
original activity of the peptide on Nav1.2 and Nav1.4 (34). Ulti-
mately, the first disulfidebridgewas excluded inour chimericpep-
tide. The resulting peptidewas named “Mini peptide” by reason of
its sequence of only 13 AAs (Table 1B). This renders the Mini
peptideevenshorter thanthesmallest-conotoxinknowntodate.
TABLE 1
Sequences of naturally occurring-conotoxins and synthetically designed peptides
Shown are the sequences of the 19 known, naturally occurring -conotoxins (A), the two naturally occurring peptides KIIIA and BuIIIC from which the Mini peptide was
derived and the artificially designedMini peptide (B), and the three series of synthetic derivatives (C).Dashes are put in the sequences tomake all sequences and intercysteine
loops of comparable length. “AAs” represents the total number of residues. The first sequence of all series is the sequence of the peptide fromwhich the series is derived (e.g.
theMini peptide orMidi peptide). Residue numbers are indicated below the corresponding sequences. Black lines above the sequences, disulfide bridges; asterisks, deletions
of Cys residues; red amino acids, changes as comparedwith the sequence of theMini peptide (Series 1) or with theMidi peptide (Series 2 and 3); number sign (#), C-terminal
amidation; Z, pyroglutamate; O, hydroxyproline. AAs in gray lie in the first intercysteine loop, AAs in turquoise lie in or are derived from the second intercysteine loop, and
AAs in green lie in or are derived from the third intercysteine loop.
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First Series of Analogues—Its short sequence makes theMini
peptide an interesting starting point for further structure-func-
tion optimization. Therefore, three series of peptides were
developed based on theMini peptide (overview in Table 1C). In
a research study, Zhang et al. (35) nicely demonstrated the
importance of several residues in KIIIA by means of an alanine
scan. The original KIIIA peptide has a slight preference for the
Nav1.2 over the Nav1.4 isoform (Table 2) (22). One of the ana-
logues that was tested in the study, KIIIA(K7A), strongly influ-
enced the discrimination between Nav1.2 and Nav1.4 (Table 2).
We integrated this in our design strategy, resulting in the
two analogues Mini-R5A and Mini-R5E. A third peptide was
based on results of Han et al. (34). They established that the
adjacent Ser5 and Ser6 in KIIIA could be replaced by a PEG
backbone without severely affecting the block on Nav1.2
(Table 2). This prompted us to hypothesize that Ser4 in the
Mini peptide may also be excluded. The resulting peptide
was named Extra-Mini as it contained only 12 AAs. The last
peptide in this series was namedMidi peptide and comprised
one extra Ala. It was incorporated where initially the third
Cys residue was removed in KIIIA/BuIIIC. This was con-
ducted to restore the appropriate spacing as we suspected
spacing to be important for the correct formation of the
-helix (36) (Table 1C, Series 1).
Second Series of Analogues—Because the Midi peptide of
Series 1 exhibited the best results of all tested peptides (see
“Electrophysiological Characterization”), we started from this
sequence in developing the second series of peptides. In EAD-
Midi andEAK-Midi, a negative chargewas removed in the third
loop; instead, a neutralizing Ala was incorporated. This was
done in accordance with results of Schroeder et al. (37), who
demonstrated that removing Asp15 in SIIIA (Conus striatus)
caused a 10-fold increase in Nav1.2 affinity, resulting in a
70-fold neuronal selectivity of Nav1.2 over Nav1.4. We com-
bined this with the addition of extraC- andN-terminal residues
to examine the influence of positive or negative charges. N-ter-
minally, an extraGluwas integrated. C-terminally, an extraAsp
providing a negative charge or a Lys providing a positive charge
was incorporated (Table 1C, Series 2). Finally, to further
explore the effects of spatial distance in the Midi peptide, one
extraAlawas integrated in theMidi sequence immediately next
to the first extra Ala. This gave rise to AA-Midi (Table 1C,
Series 2).
Third Series of Analogues—The Midi peptide acted once
more as our starting point for the third series of peptides. This
series was based on the general knowledge that basic residues
are important for binding of -conotoxins (38, 39). Likewise,
the analog SIIIA(H16R) was 137 times more selective for the
neuronal Nav1.2 isoform compared with Nav1.4 (37). We
endeavored to obtain a similar selectivity profile by replacing
His10 with an Arg in the Midi peptide. Furthermore, we inves-
tigated the effect of introducing similar mutations in the first
and second loops and altered Asn2 and Ser4 individually into
Arg. The resulting peptides were namedR1-Midi, R2-Midi, and
R3-Midi (Table 1C, Series 3).
Folding ofMini and Analogues
To investigate the folding of the Mini peptide, changes in
HPLC retention time were followed and compared with the
retention time of the reduced peptide (supplemental Fig. S1).
When the first folding strategy was used, folding was rather
slow and resembled the slow rearrangement folding of GIIIA
from Conus geographus (23). HPLC profiles of aliquots
quenched at 30 s, 30 min, 60 min, and 24 h displayed minor
accumulation of the folded Mini peptide. Only after 1 week
was a clear accumulation of folded peptide observed with
minor traces of the non-folded forms. After 1 month, the
HPLC profile did not differ significantly from that witnessed
after 1 week, suggesting that folding reached a maximum
after 1 week. The second folding strategy rather resulted in a
rapid collapse pattern and reached a maximum after 30 min
(supplemental Fig. S1). This is comparable with the folding
of PIIIA (Conus purpurascens) and SmIIIA (Conus stercus-
muscarum) (23). To confirm folding, HPLC peaks were
freeze-dried and analyzed by means of electrospray ioniza-
tion MS. The corresponding molecular masses indicated
that theMini peptide was folded (monoisotopic mass, 1621.8
Da; calculatedmass, 1620.8 Da). For all analogues of theMini
peptide, the second method was used as folding strategy
(data not shown).
Electrophysiological Characterization
Mini Peptide—The effects of the Mini peptide were evalu-
ated on a series of Nav isoforms expressed in X. laevis
oocytes. The Mini peptide reduced the peak Na current in
all tested isoforms. At 20 M, the largest block was seen on
Nav1.2 (63.3  4.9%) followed by Nav1.4 (46.6  1.8%) and
Nav1.6 (37.9  3.9%). A minor effect was noticed on Nav1.5
(15.4  2.7%), Nav1.7 (19.9  4.3%), and Nav1.8 (17.3 
4.2%). On Nav1.3, a median effect was established (36.6 
3.7%) (Fig. 1).
Series 1—R5E-Mini, R5A-Mini, and Extra-Mini exhibited a
minor to no block on Nav1.2, Nav1.4, and Nav1.6 at 75 nM (Fig.
2, Series 1). Only concentrations starting from 10 Mwere able
TABLE 2
Comparison of activities of Mini and analogues with other-conotoxins
Percentages of block are given asS.D. —, not determined for that isoform.
Concentration Nav1.2 Nav1.4 Ref.
BuIIIC 1 M — 96 21
KIIIA 1 M 90 3.3 86 5.6 35
KIIIA(K7A) 1 M 80 5.9 32 5.7 35
KIIIA(C1A,C9A) 1 M 93 2.0 85 2.0 34
Mini 20 M 63.3 4.9 46.6 1.8 This study
Midi 1 M 88.8 2.0 83.3 2.4 This study
R1-Midi 1 M 91.23 0.5 74.4 1.3 This study
R2-Midi 1 M 95.5 0.7 76.6 This study
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to induce a small block on these three isoforms (data not pre-
sented). TheMidi peptide in contrast displayed amajor block of
52.2 1.2% on Nav1.2 at 75 nM. Consequently, blocking char-
acteristics of theMidi peptide were further examined, and con-
centration-response curves were fitted (Fig. 3A). IC50 values
were 77.8  5.9 nM for Nav1.2, 53.4  2.0 nM for Nav1.4,
2373.1  94.1 nM for Nav1.5, and 115.7  27.4 nM for Nav1.6.
Nav1.3 and Nav1.5 could only be blocked with concentrations
starting from100 nM.When a concentration of 10Mwas used,
both isoforms were blocked around 40%. As such, the corre-
sponding IC50 values are of relative meaning, and represented
concentration-response curves are only based on the available
data up to 10 M.
Series 2—Unfortunately, all three peptides of the second
series (EAD-Midi, EAK-Midi, and AA-Midi) exhibited minor
to no block onNav1.2 at a concentration of 75 nM (less than 5%;
Fig. 2, Series 2). The block only started from concentrations in
the micromolar range. The equivalent was observed for iso-
forms Nav1.4 and Nav1.6 where the block also only started at
micromolar concentrations (data not presented).
Series 3—The last series of peptides comprises R1-Midi,
R2-Midi, and R3-Midi. R1-Midi had an activity profile compa-
rable with the Midi peptide. Likewise, it offered a comparable
inhibition of the current of Nav1.2 at 75 nM. R3-Midi presented
a somewhat weaker inhibition (only 37.0  5.7%). R2-Midi on
the contrary displayed a large block on Nav1.2, and thus,
R2-Midi appeared to be the most potent blocker of all peptides
tested (Fig. 2, Series 3). A concentration-response curve for
R2-Midi was constructed for Nav1.2, yielding an IC50 value of
34.1 0.01 nM (Fig. 3B).
Comparison of the Effects of the ThreeMost Interesting
Peptides
When comparing the effects of 75 nM Midi on different iso-
forms, it was observed that Midi blocked Nav1.2 to a similar
extent as Nav1.4 (52.2 versus 51.7%, respectively) followed by
Nav1.6 (41.2%). The isoforms Nav1.3, Nav1.5, and Nav1.8 were
not blocked by Midi at 75 nM (Fig. 4). R1-Midi, however, made
a clear distinction between Nav1.2 (56.0  1.9%) over Nav1.4
(39.7 2.6%) andNav1.6 (only 22.5 2.5%). R2-Midi displayed
the largest block of all three peptides on Nav1.2 (70.3 2.4%).
Furthermore, 75 nM R2-Midi exhibited a block of 45.5  0.7%
on Nav1.4 and 45.5 1.1% on Nav1.6 (Fig. 4).
When a one-way analysis of variance Bonferroni statistical
analysis was performed on these results, Midi differed signifi-
cantly for Nav1.2 compared with the other isoforms (p 0.05).
However, the block was not significantly different for Nav1.2
compared with Nav1.4. The same holds true for Nav1.3 against
Nav1.5 and Nav1.8 (p  0.05). The effects of R1-Midi differed
significantly for Nav1.2 set against all other isoforms (p 0.05).
For Nav1.3, Nav1.5, and Nav1.8, no significant differences were
observed. For R2-Midi, comparable degrees of block were
noticed on Nav1.4 and Nav1.6 and on Nav1.5 and Nav1.8 (p 
0.05). Interestingly, the residual currents on Nav1.2 displayed
by R1-Midi (9.8 0.5%) and R2-Midi (4.5 0.7%) were some-
what larger than the residual current displayed by Midi itself
(1.2 1.1%).
FIGURE 1.Block of different Nav isoforms by 20MMini peptide.Currents
from voltage-clamped X. laevis oocytes were measured as described under
“Experimental Procedures.” The Mini peptide was tested on Nav1.2–Nav1.8.
Mean percentages of block are calculated for each isoform for at least three
experiments (for Nav1.7 and Nav1.8, n 2), and S.E. is indicated by error bars,
if appropriate. Mini preferentially blocks Nav1.2 (63.3  4.9%) over Nav1.4
(46.6  1.8%) and Nav1.6 (37.9  3.9%), respectively. Percentages of block
were as follows for other isoforms (mean S.E.): Nav1.3, 36.6 3.7%; Nav1.5,
15.4 2.7%; Nav1.7, 19.9 4.3%, and Nav1.8, 17.3 4.2%.
FIGURE 2. Representative current traces of all peptides of Series 1, 2, and
3 at 75 nM onNav1.2. Traces were obtained by two-electrode voltage clamp
on X. laevis oocytes expressing theNav1.2 isoform as described under “Exper-
imental Procedures.” Currents were evoked by a depolarizing pulse starting
from a holding potential of 90 mV to the voltage corresponding to the
maximal activation in control conditions. Asterisks indicate the steady-state
peak amplitude of the currents after exposure to the toxins. Because theMini
peptide preferentially blocked Nav1.2, this isoform was chosen to illustrate
representative blocking activities of the other series. The most potent block-
ers are Midi (traces represented here; 52.88% of block), R1-Midi (54.32% of
block), and R2-Midi (70.9% of block). Scale bars, 5 ms for horizontal lines and
0.5 A for vertical lines.
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Kinetics and Voltage Dependence of Block
To investigate the reversibility of block and determine kinet-
ics of block ofMidi, R1-Midi, and R2-Midi, washouts were con-
ducted on Nav1.2. For all peptides, the block could be reversed,
albeit often very slowly. Therefore, exact kinetics of block could
not be determined. Effects on the voltage dependence of acti-
vation and steady-state inactivationwere analyzed forMidi and
R2-Midi on Nav1.2. No shifts were observed in the activation
and steady-state inactivation curves of Midi and R2-Midi (sup-
plemental Fig. S2).
NMR Spectroscopy
The solution structure of the Midi peptide was determined
by NMR spectroscopy. The quality of the calculated structure
was evaluated by means of the root mean square deviation val-
ues from the average structure (Table 3). The Midi peptide
adopted a flexible structure without the typical -helix
observed in -conotoxins (Fig. 5A). Its N- and C-terminal
regions differed greatly from the corresponding regions in
KIIIA(C1A,C9A) in which the same disulfide bridge was
removed as for the Midi peptide. However, some key basic res-
idues appeared to be distributed in a manner similar to that in
KIIIA(C1A,C9A) (Fig. 5B). Models of KIIIA(C1A,C9A) were
generated using the solution structure deposited in the
BioMagResBank (accession number 20049) by Khoo et al. (36).
The solution structure of theMidi peptide was deposited in the
Protein Data Bank under code 2LU6.
DISCUSSION
In current study, we demonstrate a successful strategy to
design small subtype-selective compounds. A series of 11 pep-
tides were developed, all of which established a block on Navs.
The initial Mini peptide demonstrated activities at micromolar
FIGURE 3. Concentration-response curves for the Midi peptide and
R2-Midi.A, Midiwas tested in different concentrations on a rangeof isoforms
to obtain the corresponding IC50 values. B, R2-Midi was tested in different
concentrations on Nav1.2. The asterisk indicates the IC50 value of R2-Midi on
Nav1.2, being 34.1 nM  0.01. Currents were obtained as described under
“Experimental Procedures.” The percentage of block was plotted against the
logarithm of the tested concentrations. For all Nav isoforms, results were fit
with the Hill equation. IC50 values of the Midi peptide were 77.8 5.9 nM for
Nav1.2, 53.42.0 nM forNav1.4, 2373.194.1 nM forNav1.5, and115.727.4
nM forNav1.6. IC50 values forNav1.3 andNav1.5 are of relativemeaningas they
are only blocked by concentrations starting from 100 nM.
FIGURE 4.Overviewof blockbyMidi, R1-Midi, andR2-Midi. The three pep-
tides were tested on Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, and Nav1.8 at a
concentration of 75 nM. When no block is seen at that concentration, this is
represented by an arbitrary value of 1% for the clarity of the figure. This is the
case for Midi on Nav1.3, Nav1.5, and Nav1.8 and for R1-Midi and R2-Midi on
Nav1.5 and Nav1.8. Other specific values are discussed under “Results.” Data
are representedas themeansS.E. (indicatedby error bars); eachexperiment
was performed at least three times (n 3).
TABLE 3
Structure statistics of the Midi peptide derived from NMR structural
analysis
r.m.s.d., root mean square deviation.
Quantity Value
Total unambiguous distance restraints 179
Intraresidual 128
Sequential (i j 1) 34
Medium (2 i j  4) 10
Long range (i j  5) 7
Dihedral angles 29
r.m.s.d. from the average atomic coordinates (Å)
Backbone (N, C, C) 3.41 1.67
Heavy atoms 2.63 1.31
Deviation from idealized covalent geometry
Bond (Å) 0.0006 0.0000
Angles (°) 2.882 0.085
Improper (°) 2.323 0.521
Ramachandran analysis (%)
Residues in most favored regions 49.6
Residues in additional allowed regions 49.6
Residues in generously allowed regions 0.8
Residues in disallowed regions 0
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concentrations. KIIIA and Mini have identical selectivity pro-
files, and both block Nav1.2 to a larger extent than Nav1.4
(Table 2) followed by Nav1.6 (35, 36). This might in part be
caused by the presence of a Trp residue (Trp6 inMini and Trp8
in KIIIA) as suggested previously (22, 35).
An extra Ala residue added to the sequence of the Mini pep-
tide to restore the spacing (in comparison with the original
-conotoxins) led to a peptide active in nanomolar concentra-
tions. Thismay imply that the difference in biological activity of
Mini (in a micromolar range) and Midi (in a nanomolar range)
can be due to a difference in spacing and that at least six resi-
dues are required to set up a fully functional bioactive scaffold
that can interact properly with a binding area on the Nav chan-
nel (37). Interestingly, an -helix does not appear to be strictly
necessary for the biological activity of -conotoxins because
this structure was not identified within the Midi peptide as
defined by NMR. In KIIIA, this -helix is situated between Lys5
and His12 (36).
KIIIA and Midi exhibit comparable potencies with IC50 val-
ues on Nav1.2, Nav1.4, and Nav1.6 around nanomolar concen-
trations (22). Notwithstanding the nearly complete block on
Nav1.4 byBuIIIC at 1M,Midi demonstrated a smaller block on
Nav1.4 at the same concentration (Table 2). Moreover, the
block is only complete at a 10-fold higher concentration. Pos-
sibly, the bulky structure of BuIIIC (27 AAs) allows a more
complete occlusion of the Na conduction pathway at lower
concentrations. Besides a larger steric hindrance of Na ions
for BuIIIC, additional positive charges in BuIIIC can cause a
larger electrostatic repulsion than for the Midi peptide. The
mutant R2-Midi in which an extra positive charge also leads to
lower IC50 values confirms this hypothesis, which was also pro-
posed previously (40).
Spacing is important for the activity of the Midi peptide.
However, this also applies to the Extra-Mini peptide in which
Ser4 was additionally eliminated. Our results indicate that this
distorts the formation of a bioactive scaffold. This probably
hinders the appropriate binding of its key residues to the Nav
channel. Once Arg5 in Mini was replaced either by an Ala
resulting in Mini-R5A or by a Glu resulting in Mini-R5E, activ-
ities were also severely affected. This concurs with previous
studies in which the corresponding Arg was suggested to be
determinant for block of Nav1.2 and Nav1.4 (35, 37, 41).
For the second series of peptides, additional N- and C-termi-
nal residues were added to the sequence ofMidi. This was com-
bined with modification of Asp9 into Ala. Our results do not
correspond to those of Schroeder et al. (37). They demon-
strated that replacement of the corresponding Asp15 in SIIIA
led to a more selective Nav1.2 block. For our peptides EAD-
Midi and EAK-Midi, blocking activity was nonetheless seri-
ously affected. However, our results correspond partially to
those obtained for an analog of KIIIA.WhenAsp11 inKIIIAwas
replaced by Ala, this caused a small reduction in block of 5% for
Nav1.2 and a large reduction in block of 45% for Nav1.4 (calcu-
lated fromdata of Ref. 35). In the EAD- andEAK-Midi peptides,
the simultaneous introduction of three mutations at once was
probably a deleterious combination.
The final series of peptides provided us with interesting data
concerning the role of basic residues in the interactions of
-conotoxins with Nav channels. The importance of basic res-
idues in the binding of the-conotoxins with Nav channels has
been established previously. Residue Arg13 of GIIIA has been
one of the most intensively studied residues in this respect. It
was established to bind to a negative charge (Glu758) in DII of
Nav1.4 (42). Likewise, interactions were demonstrated between
Arg19 of GIIIA and residues Asp762 and Glu765 in the P-S6 loop
of DII of Nav1.4 (43). Based on the potent block of R1-Midi and
R2-Midi on Nav1.2, Nav1.4, and Nav1.6, it can be stated that
basic amino acids are key residues for a strong binding of the
peptide to the channel (Fig. 4). Nevertheless, the most striking
compound in this series is undoubtedly R2-Midi because this
compound exhibits a very potent and selective block onNav1.2.
Consequently, this makes R2-Midi an interesting compound
for development as a therapeutic agent in Nav1.2-related dis-
eases such as epilepsy.
As demonstrated for KIIIA (22), SIIIA (15), PIIIA (41), and
certain derivatives of GIIIA (40), the block was never complete
FIGURE5.NMRstructureof theMidipeptide.A, stereoviewsof a familyof 20
final structures of the Midi peptide superimposed over backbone heavy
atoms (N, C, and C) with disulfide bonds colored gold. B, front and back
views of the closest-to-average structure of the Midi peptide (top) and
KIIIA(C1A,C9A) where the first disulfide bridge is removed (bottom) with side
chain heavy atoms of key residues displayed and labeled. Disulfide bridges
are colored gold, positively charged residues are blue, negatively charged
residues are red, hydrophilic residues are green, and aromatic residues are
magenta. The twoviews are relatedbya180° rotation around thevertical axis.
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for any of the peptides that could be tested at their maximum
concentrations (e.g.Midi, R1-Midi, and R2-Midi). Charge-neu-
tralizing substitutions at three positions in PIIIA also caused a
residual current. It was suggested that its basic residues interact
with channel residues close to the Na conduction pathway.
Thereby, the pore of the channel is blocked electrostatically or
sterically (41). However, this toxin-channel interaction could
allow some Na ions or even tetrodotoxin to sneak by, causing
a residual current (12, 16, 24, 40). A small residual current was
similarly observed for derivatives ofGIIIA at one single position
(Arg13). Nonetheless, following this reasoning, R1-Midi and
R2-Midi should cause more electrostatic repulsion compared
with Midi due to the addition of a positive Arg. Their residual
currents should be smaller as opposed to those of the Midi
peptide. However, this is not the case. Possibly, there are sup-
plementary, non-electrostatic components that contribute to
the mechanism of block observed for R1-Midi and R2-Midi.
Recently, it was proven by molecular dynamic simulations for
PIIIA that differences in binding affinity on Nav1.4 can be due
to a slightly different location of binding in the pore region.One
of its structural isomers was simulated to bind to a region
located deeper in the pore, correlating to a higher binding affin-
ity on Nav1.4 (44). Consequently, small differences in binding
affinities reveal that our-conotoxin derivatives bind at slightly
different regions, although all located in the pore and therefore
leading to block of Na conduction.
Interestingly, our NMR data indicate that Midi adapts a
rather flexible structure devoid of an -helix. All 3JHNH cou-
pling constants extracted from double quantum-filtered COSY
spectra (measured at 5 °C; data not displayed) are between 6
and 8Hz, indicative of a very flexible structure. Despite the lack
of an -helix, the Midi peptide blocks Navs at nanomolar con-
centrations. This is in accordwith recent studies of an isomer of
PIIIA that also had a flexible conformation but remained active
onNav1.4 (44). Apparently, an-helix is not strictly essential to
acquire a fully active peptide. Possibly, some of the basic resi-
dues incorporated in theMidi peptide are distributed in aman-
ner close to the arrangement in KIIIA(C1A,C9A) (Fig. 5B),
leading to a similar activity profile. Further evidence is pre-
sented by Chen and Chung (45), who suggest that PIIIA may
block the Nav with various binding modes. Different basic res-
idues can thereby all protrude into the selectivity filter and
block the pore, whereas other residues can make electrostatic
contacts at the outer vestibule of the channel. Because the basic
residues of Midi are also symmetrically distributed, this allows
the peptide to formmultiple bindingmodes with the Nav chan-
nel. It will be interesting to generate molecular dynamics sim-
ulations for Midi as well.
For a peptide to be eligible for development as a therapeutic
compound, it is essential that it remains stable in vivo. To
improve stability, cyclic peptides or lactam-stabilized peptides
can be formed (46). This can for instance be achieved bymeans
of native chemical ligation (for a review, seeRef. 47). Regardless,
whether these modifications do not influence the activities of
the peptides and whether they still exhibit the same potencies
as the original peptides need be determined.
With our results, we prove that it is possible to design very
small peptides based on knownpharmacophores of-conotox-
ins without losing their potency and therapeutically important
selectivity. We confirm that removal of one disulfide bridge
does not affect their activity. By defining the NMR structure of
the Midi peptide, we deliver evidence that the -helical struc-
ture that has traditionally been considered as responsible for
the biological activity of -conotoxins is not strictly necessary.
Finally, we demonstrate that it is possible to obtain more selec-
tive peptides by thoughtfullymutating particular amino acids in
the sequence of -conotoxins. Therefore, our miniaturized
compounds are an ideal starting platform in the pursuit of novel
therapeutics that can be used to treat Nav-related diseases such
as epilepsy (48) and pain (34, 35).
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